Key result
Adding ezetimibe to high-dose statins proves cost-effective at ~$20,242 per QALY versus PCSK9 inhibitors.
Why the study?
International guidelines recommend add-on ezetimibe and PCSK9 inhibitors for secondary prevention of CVDs, but whether these regimens fit the Chinese healthcare system economically remains unclear.
Is adding ezetimibe and/or PCSK9 inhibitors to high-dose statins cost-effective for secondary prevention of cardiovascular disease in Chinese adults?
Population
Chinese adults receiving high-dose statins for secondary prevention of CVDs
Comparison
High-dose statin-only vs ezetimibe plus statin vs PCSK9 inhibitors plus statin vs PCSK9 inhibitors plus ezetimibe plus statin
Design
Markov model simulation study
Follow-up
20 yr
Authors
Loading...
Supports ezetimibe addition for secondary prevention in China; leaves open whether PCSK9i price cuts achieve cost-effectiveness thresholds.
Is adding ezetimibe and/or PCSK9 inhibitors to high-dose statins cost-effective for secondary prevention of cardiovascular disease in Chinese adults?
Effect estimate: ICER US$20,242 per QALY for adding ezetimibe
In Chinese adults on high-dose statins for secondary CVD prevention, adding ezetimibe is cost-effective, whereas adding PCSK9 inhibitors requires a substantial price reduction to meet cost-effectiveness thresholds.
Xiang et al. (2023) studied Cardiovascular disease. Ezetimibe and/or PCSK9 inhibitors vs. High-dose statin-only was evaluated on Incremental cost-effectiveness ratio (ICER) per quality-adjusted life year (QALY) (ICER US$20,242 per QALY for adding ezetimibe). In Chinese adults on high-dose statins for secondary CVD prevention, adding ezetimibe was cost-effective (ICER US$20,242/QALY) compared to adding PCSK9 inhibitors or both drugs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: